ReviewJournal of orthopaedic translation2023
Muscle-bone crosstalk via endocrine signals and potential targets for osteosarcopenia-related fracture.
Review in Journal of orthopaedic translation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 56 citations in OpenAlex.
- Denosumab Versus Zoledronic Acid for Muscle Strength and Physical Performance in Postmenopausal Osteoporosis: A 3-Year Prospective Study.Journal of cachexia, sarcopenia and muscle · 2026Observational
- Exosome-mediated muscle-bone crosstalk: mechanisms and therapeutic potential.Journal of translational medicine · 2026Review
- Maternal Exercise Rescues Embryonic Osteogenesis Impaired due to POLG Mutation Through a Potential Apelin-ATF4 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Rhythmic Metabolism in Osteosarcopenia: Emerging Evidence, a Chronometabolomic Framework for the Bone-Muscle Unit, and Research Priorities.Metabolites · 2026Review
- Lonafarnib clinical trials demonstrate uncoupling of the muscle-bone unit in Hutchinson-Gilford Progeria Syndrome.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026Article
- Fully automated system predicts osteoporotic vertebral fracture across institutions using lumbar MRI paraspinal muscle signatures.NPJ digital medicine · 2026Article
- Muscle and bone: not just neighbours, but interdependent teammates in wheelchair users.European journal of applied physiology · 2026Article
- The Rising Burden of Osteosarcopenia in Older Adults: A Narrative Review of Pathophysiology, Diagnostic Challenges, and Therapeutic Perspectives.Health science reports · 2026Article
- Coordinated Bone-Muscle Axis Association in South China Carp (Foods (Basel, Switzerland) · 2026Article
- Decoding cellular communication networks and signaling pathways in bone, skeletal muscle, and bone-muscle crosstalk through spatial transcriptomics in a young male mouse.Bone research · 2026Article
- The crossroads between osteosarcopenia and intrinsic capacity-a narrative review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Review
- Protective effects of irisin in sarcopenia: a promising treatment.Journal of orthopaedic translation · 2026Review
- Cross-talk of gut-bone-muscle: osteosarcopenia in experimental colitis models.Laboratory animal research · 2026Review
- Human Umbilical Cord-Derived Mesenchymal Stem Cells-Involved Strategies: Advancing Tendon Injuries Therapy Towards Clinical Translation.Stem cell reviews and reports · 2026Review
- Exercise alleviates cognitive dysfunction in Alzheimer's disease mice via skeletal muscle-derived extracellular vesicles that enhance plaque clearance by microglia.Nature aging · 2026Article
- LDL receptor affects the skeletal muscle and bone microstructure of female mouse through the Wnt/β-catenin signaling pathway.Journal of molecular histology · 2026Article
- Branched‑chain amino acid metabolism and bone metabolism: Implications for osteoporosis pathogenesis and therapeutic strategies (Review).International journal of molecular medicine · 2026Review
- Modulating iMSC Spheroid Function with Mechanically Tunable Hydrogels to Strengthen the Bone-Muscle Axis.ACS biomaterials science & engineering · 2026Article
- Body composition-derived principal components partially explain sex and age effects on bone mineral density in type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Determinants and predictive performance of reduced muscle mass in elderly patients with type 2 diabetes: a retrospective study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcopenia is a syndrome coexisting sarcopenia and osteopenia/osteoporosis, with a high fracture risk. Recently, skeletal muscle and bone have been recognized as endocrine organs capable of communication through secreting myokines and osteokines, respectively. With a deeper understanding of the muscle-bone crosstalk, these endocrine signals exhibit an important role in osteosarcopenia development and fracture healing. Methods: This review summarizes the role of myokines and osteokines in the development and treatment of osteosarcopenia and fracture, and discusses their potential for osteosarcopenia-related fracture treatment. Results: Several well-defined myokines (myostatin and irisin) and osteokines (RANKL and SOST) are found to not only regulate skeletal muscle and bone metabolism but also influence fracture healing processes. Systemic interventions targeting these biochemical signals has shown promising results in improving the mass and functions of skeletal muscle and bone, as well as accelerating fracture healing processes. Conclusion: The regulation of muscle-bone crosstalk via biochemical signals presents a novel and promising strategy for treating osteosarcopenia and fracture by simultaneously enhancing bone and muscle anabolism. We propose that myostatin, irisin, RANKL, and SOST may serve as potential targets to treat fracture patients with osteosarcopenia. The translational potential of this article: Osteosarcopenia is an emerging geriatric syndrome where sarcopenia and osteoporosis coexist, with high fracture risk, delayed fracture healing, and increased mortality. However, no pharmacological agent is available to treat fracture patients with osteosarcopenia. This review summarizes the role of several myokines and osteokines in the development and treatment of osteosacropenia and fracture, as well as discusses their potential as intervention targets for osteosarcopenia-related fracture, which provides a novel and promising strategy for future osteosarcopenia-related fracture treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.